The ready-to-dilute liquid formulation of Akynzeo® (fosnetupitant/palonosetron; Helsinn) injection is now available for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.
Akynzeo is a combination of palonosetron, a 5-HT3 receptor antagonist, and fosnetupitant (a prodrug of netupitant), a substance P/NK1 receptor antagonist. Palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
The new liquid formulation of Akynzeo injection is supplied as a solution containing 235mg fosnetupitant/0.25mg palonosetron in a single-dose 20mL vial. The product does not require reconstitution or refrigeration and may be stored for up to 24 hours at room temperature after dilution. Additionally, it is compatible with intravenous dexamethasone sodium phosphate which can be added to the Akynzeo solution or infused simultaneously.
“We are very pleased to launch the new IV solution of Akynzeo, which provides customers with operational advantages for storage, handling, preparation, and administration. We hope that these features will be of assistance to those administering the treatment, allowing for greater efficiency as they help prevent CINV in patients undergoing chemotherapy,” said Paul Rittman, CEO, Helsinn Therapeutics (US), Inc.
Akynzeo is also available for injection as a lyophilized powder for reconstitution in a single-dose vial for the same indication. Additionally, Akynzeo is supplied in a capsule formulation indicated for use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Akynzeo injection and Akynzeo for injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.
For more information visit akynzeo.com.
- Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US. https://www.globenewswire.com/news-release/2020/08/20/2081366/0/en/Helsinn-Group-announces-AKYNZEO-injection-a-new-liquid-IV-solution-now-available-in-the-US.html. Accessed August 20, 2020.
- Akynzeo [package insert]. Iselin, NJ: Helsinn Therapeutics (US), Inc; 2020.